Gbola Amusa

Amid chatter that Moderna's Inc (NASDAQ: MRNA) investigational coronavirus vaccine is pricier relative to rivals, the company offered some clarity on pricing on its earnings call. An analyst at Chardan detailed COVID-19 vaccine pricing dynamics in a Thursday note.  The Moderna...

Adverum Biotechnologies Inc (NASDAQ: ADVM) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort...

The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. From the low, the stock rallied to an intraday peak of $38.96 on July 11, 2019, a 133%...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) has sparked a rally in the latter's shares. The Analysts Chardan analyst Gbola Amusa maintained a Neutral on Spark and lifted the...

Tocagen Inc (NASDAQ: TOCA), which focuses on developing cancer-selective gene therapies based on a retroviral replicating vector platform, has earned a bullish review from Chardan. The Analyst Analyst Gbola Amusa initiated coverage of Tocagen with a Buy rating and $30 price target, suggesting...

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced a manufacturing-related hold Wednesday on its Phase 1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy. Solid Biosciences Inc (NASDAQ: SLDB) fell in sympathy, but the competitor could benefit from Sarepta’s delay. The...

The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The Rating Chardan analyst Gbola Amusa maintained a Buy rating on the stock, but increased his price...

Shares of Crispr Therapeutics AG (NASDAQ: CRSP) fell more than 7 percent Thursday morning after the U.S. Food and Drug Administration said it placed a clinical hold on the company's therapy. What Happened The FDA placed a clinical hold on the Investigational New Drug application for Crispr...

Uniqure NV (NASDAQ: QURE) struck all-time highs last week and continued to linger near its peak value. One analyst projects 61-percent upside and considers the equity a top pick in 2018.  The Rating Chardan analyst Gbola Amusa maintained a Buy rating on uniQure and increased the price target...

Assembly Biosciences Inc (NASDAQ: ASMB) made a poster presentation of interim results from two early-stage studies for its ABI-H073, a hepatitis B virus core protein allosteric modulator, at the EASL International Liver Congress 2018 in Paris. The Analyst Chardan analyst Gbola Amusa...

Regenxbio Inc (NASDAQ: RGNX) rode a tailwind Monday from the announced acquisition of its partner AveXis Inc (NASDAQ: AVXS), and the benefits may keep coming. The Rating Chardan analyst Gbola Amusa reiterated a Buy rating on Regenxbio and increased the price target from $85 to $90. The...

AveXis Inc (NASDAQ: AVXS) announced Monday its sale to Novartis AG (ADR) (NYSE: NVS) for $8.7 billion, or $218 per share. The deal didn’t come as a complete surprise. The Rating Chardan analyst Gbola Amusa maintained a Buy rating on AveXis and increased the price target from $140 to $218...

The young biotech firm Solid Biosciences Inc (NASDAQ: SLDB) secured two Buy ratings Tuesday and another Wednesday. The Rating Chardan Capital analyst Gbola Amusa initiated Solid Biosciences with a Buy rating and $40 price target. The Thesis Amusa expects gene therapies to penetrate 26.8...